Jisheng Y. Li

State Key Laboratory Of Heavy Oil Processing And High Pressure Fluid Phase Behavior & Property Research Laboratory
Beijing, 102249, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial.

First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 26, 2026

Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China.

Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China.

Journal: Therapeutic advances in medical oncology

Published: February 27, 2026

Expert consensus on the detection and clinical application of tumor mutational burden.

Expert consensus on the detection and clinical application of tumor mutational burden.

Journal: Cancer biology & medicine

Published: February 18, 2026

A Case of Metastatic Non-small Cell Lung Cancer with Rare BRAF p.L485_T488delinsF Mutation Treated with Dabrafenib and Trametinib

A Case of Metastatic Non-small Cell Lung Cancer with Rare BRAF p.L485_T488delinsF Mutation Treated with Dabrafenib and Trametinib

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: October 29, 2025

Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058).

Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058).

Journal: Frontiers in pharmacology

Published: August 15, 2025

Clinical outcomes and safety of continuous immunotherapy beyond progression in patients with extensive-stage small cell lung cancer: a retrospective real-world study.

Clinical outcomes and safety of continuous immunotherapy beyond progression in patients with extensive-stage small cell lung cancer: a retrospective real-world study.

Journal: Frontiers in immunology

Published: August 07, 2025

International guidelines on the diagnosis and treatment of NUT carcinoma.

International guidelines on the diagnosis and treatment of NUT carcinoma.

Journal: Innovation (Cambridge (Mass.))

Published: April 11, 2025

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.

Journal: Cancer biology & medicine

Published: April 09, 2025

What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review.

What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review.

Journal: Frontiers in pharmacology

Published: February 06, 2025

Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis.

Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis.

Journal: Frontiers in pharmacology

Published: December 04, 2024

Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors.

Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors.

Journal: Global medical genetics

Published: November 25, 2024

Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors.

Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors.

Journal: BMC cancer

Published: September 14, 2024

Showing 1-12 of 55

Last Updated: 09/26/2026